HIV/AIDS

Estimation of the Potential Impact of COVID-19 Responses on the HIV Epidemic: Analysis using the Goals Model

1. John Stover
2. Newton Chagoma
3. Isaac Taramusi
4. Yu Teng
5. Rob Glaubius
6. Guy Mahiane

Reviewed by ScreenIT

COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients

1. Georg Härter
2. Christoph D. Spinner
3. Julia Roider
4. Markus Bickel
5. Ivanka Krznaric
6. Stephan Grunwald
7. Farhad Schabaz
8. Daniel Gillor
9. Nils Postel
10. Matthias C. Mueller
11. Markus Müller
12. Katja Römer
13. Knud Schewe
14. Christian Hoffmann

Reviewed by ScreenIT

A Very Flat Peak: Why Standard SEIR Models Miss the Plateau of COVID-19 Infections and How it Can be Corrected

1. Santosh Ansumali
2. Meher K. Prakash

Reviewed by ScreenIT

The role of migration networks in the development of Botswana’s generalized HIV epidemic

1. Janet Song
2. Justin T Okano
3. Joan Ponce
4. Lesego Busang
5. Khumo Seipone
6. Eugenio Valdano
7. Sally Blower

• Curated by eLife

  eLife assessment

  This valuable paper uses representative samples of micro-census data from Botswana to describe migration rates over four points in time, from 1981 to 2011. The authors use compelling descriptive data to present migration characteristics where roughly 10% of the population moved in the past year - with equal numbers of men and women, and with migration between districts more common than within districts. Preliminary data indicated migration patterns could have supported HIV diffusion, this can be a starting point for more in-depth analyses. The work will be of interest to those studying human movement and its impact on diseases.

Reviewed by eLife

Design of an optimal combination therapy with broadly neutralizing antibodies to suppress HIV-1

1. Colin LaMont
2. Jakub Otwinowski
3. Kanika Vanshylla
4. Henning Gruell
5. Florian Klein
6. Armita Nourmohammad

• Curated by eLife

  Evaluation Summary:

  This study provides computational predictions on optimal combinations of broadly neutralizing antibodies for treating HIV-1, based on the finding that population diversity alone permits the prediction of the timing of viral escape from broadly neutralizing antibodies. The idea behind the approach used is good, although the analyses and computational data/results highlight important limitations of the modeling approach. Nonetheless, the study should be of broad interest to those studying viral responses to therapeutic interventions as well as to both evolutionary and computational biologists.

  (This preprint has been reviewed by eLife. We include the public reviews from the reviewers here; the authors also receive private feedback with suggested changes to the manuscript. Reviewer #1 agreed to share their name with the authors.)

Reviewed by eLife

CLINICAL MANIFESTATIONS AND DIAGNOSIS OF CO-INFECTION OF COVID-19, TUBERCULOSIS AND OPPORTUNISTIC PULMONARY INFECTIONS IN LATE-STAGE HIV PATIENTS

1. A.V. Mishina
2. V.Yu. Mishin
3. I. V. Shashenkov

Reviewed by ScreenIT

Analysis of Severe Illness After Postvaccination COVID-19 Breakthrough Among Adults With and Without HIV in the US

1. Raynell Lang
2. Elizabeth Humes
3. Sally B. Coburn
4. Michael A. Horberg
5. Lily F. Fathi
6. Eric Watson
7. Celeena R. Jefferson
8. Lesley S. Park
9. Kirsha S. Gordon
10. Kathleen M. Akgün
11. Amy C. Justice
12. Sonia Napravnik
13. Jessie K. Edwards
14. Lindsay E. Browne
15. Deana M. Agil
16. Michael J. Silverberg
17. Jacek Skarbinski
18. Wendy A. Leyden
19. Cameron Stewart
20. Brenna C. Hogan
21. Kelly A. Gebo
22. Vincent C. Marconi
23. Carolyn F. Williams
24. Keri N. Althoff
25. Corona-Infectious-Virus Epidemiology Team (CIVETs) of the NA-ACORD of IeDEA

Reviewed by ScreenIT

Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study

1. Kathryn S. Hensley
2. Marlou J. Jongkees
3. Daryl Geers
4. Corine H. GeurtsvanKessel
5. Yvonne M. Mueller
6. Virgil A. S. H. Dalm
7. Grigorios Papageorgiou
8. Hanka Steggink
9. Alicja Gorska
10. Susanne Bogers
11. Jan G. den Hollander
12. Wouter F. W. Bierman
13. Luc B. S. Gelinck
14. Emile F. Schippers
15. Heidi S. M. Ammerlaan
16. Marc van der Valk
17. Marit G. A. van Vonderen
18. Corine E. Delsing
19. Elisabeth H. Gisolf
20. Anke H. W. Bruns
21. Fanny N. Lauw
22. Marvin A. H. Berrevoets
23. Kim C. E. Sigaloff
24. Robert Soetekouw
25. Judith Branger
26. Quirijn de Mast
27. Adriana J. J. Lammers
28. Selwyn H. Lowe
29. Rory D. de Vries
30. Peter D. Katsikis
31. Bart J. A. Rijnders
32. Kees Brinkman
33. Anna H. E. Roukens
34. Casper Rokx

Reviewed by ScreenIT

Postacute sequelae and adaptive immune responses in people with HIV recovering from SARS-COV-2 infection

1. Michael J. Peluso
2. Matthew A. Spinelli
3. Tyler-Marie Deveau
4. Carrie A. Forman
5. Sadie E. Munter
6. Sujata Mathur
7. Alex F. Tang
8. Scott Lu
9. Sarah A. Goldberg
10. Mireya I. Arreguin
11. Rebecca Hoh
12. Viva Tai
13. Jessica Y. Chen
14. Enrique O. Martinez
15. Brandon C. Yee
16. Ahmed Chenna
17. John W. Winslow
18. Christos J. Petropoulos
19. Alessandro Sette
20. Daniella Weiskopf
21. Nitasha Kumar
22. Kara L. Lynch
23. Peter W. Hunt
24. Matthew S. Durstenfeld
25. Priscilla Y. Hsue
26. J. Daniel Kelly
27. Jeffrey N. Martin
28. David V. Glidden
29. Monica Gandhi
30. Steven G. Deeks
31. Rachel L. Rutishauser
32. Timothy J. Henrich

Reviewed by ScreenIT

Deep-sequence phylogenetics to quantify patterns of HIV transmission in the context of a universal testing and treatment trial – BCPP/Ya Tsie trial

1. Lerato E Magosi
2. Yinfeng Zhang
3. Tanya Golubchik
4. Victor DeGruttola
5. Eric Tchetgen Tchetgen
6. Vladimir Novitsky
7. Janet Moore
8. Pam Bachanas
9. Tebogo Segolodi
10. Refeletswe Lebelonyane
11. Molly Pretorius Holme
12. Sikhulile Moyo
13. Joseph Makhema
14. Shahin Lockman
15. Christophe Fraser
16. Myron Max Essex
17. Marc Lipsitch
18. On behalf of The Botswana Combination Prevention Project and PANGEA consortium

• Curated by eLife

  Evaluation Summary:

  One hypothesis to explain recent worse-than-expected outcomes of universal test-and-treat HIV prevention trials is population mobility. The authors show phylogenetically that mobility could play a role in transmission events in a large trial in Botswana. This study is of public health interest, has a large sample size for a phylogenetic study in this setting, and overall precise analysis. A few methodological clarifications are still needed to ensure that the data supports the study's claims.

  (This preprint has been reviewed by eLife. We include the public reviews from the reviewers here; the authors also receive private feedback with suggested changes to the manuscript. Reviewer #1 agreed to share their name with the authors.)

Reviewed by eLife